LFA-1 regulated by IL-2/STAT5 pathway boosts antitumor function of intratumoral CD8+ T cells for improving anti-PD-1 antibody therapy
Anti-PD-1 antibody therapy has achieved success in tumor treatment; however, the duration of its clinical benefits are typically short. The functional state of intratumoral CD8+ T cells substantially affects the efficacy of anti-PD-1 antibody therapy. Understanding how intratumoral CD8+ T cells chan...
| Egile Nagusiak: | , , , , , , , , |
|---|---|
| Formatua: | Artikulua |
| Hizkuntza: | English |
| Argitaratua: |
Taylor & Francis Group
2024-12-01
|
| Saila: | OncoImmunology |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2293511 |